Advertisement
UK markets open in 6 hours 56 minutes
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • CRUDE OIL

    82.79
    -0.02 (-0.02%)
     
  • GOLD FUTURES

    2,328.50
    -9.90 (-0.42%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • Bitcoin GBP

    51,546.81
    -1,840.60 (-3.45%)
     
  • CMC Crypto 200

    1,388.70
    -35.40 (-2.49%)
     
  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     
  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     

Depomed versus Peers in March 2018: Analyst Ratings

Depomed versus Peers in March 2018: Analyst Ratings

Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions. In March 2018, two of the seven analysts covering Depomed have given the stock a “buy” rating. By comparison, of the 22 analysts covering Merck (MRK) in March 2018, six analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating, while nine analysts have given it a “hold” rating.